Indacaterol and Mometasone

Bronchodilator & Anti-asthma Preps: Inhalants · Beta-2 agonist/Corticosteroid

Indications

Maintenance treatment of asthma not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.

Dosage

Cap for Inhalation: Adults and Children =12 yrs: One capsule to be inhaled once daily. Max: 125/250 mcg once daily. Children <12 yrs: Not recommended.

Adverse Effects

Upper respiratory tract infection, headache, asthma (exacerbation), oropharyngeal pain, dysphonia, musculoskeletal pain.

Risk Factor (Pregnancy/Lactation)

Precautions: Cardiovascular disorders (coronary artery disease, acute MI, cardiac arrhythmias, hypertension), convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta2-adrenergic agonists. Pregnancy. Lactation.

Interactions

MAOIs, tricyclic antidepressants, medicinal products known to prolong the QT interval, methylxanthine derivatives, steroids, non-potassium-sparing diuretics.

Advice to Patient

The capsules must only be removed from the blister immediately before use. The capsules must be administered only using the inhaler provided with each new prescription. After inhalation, rinse mouth with water without swallowing.

Pharmacokinetics

Bioavailability: Indacaterol: 45%. Mometasone: <10%. Metabolism: Indacaterol: Hepatic. Mometasone: Hepatic. Half-life elimination: Indacaterol: 40-52 hrs. Mometasone: Terminal: Approx. 4.5 hrs. Time to peak, plasma: Indacaterol: Approx. 15 mins. Mometasone: 1 hr. Excretion: Indacaterol: Faeces (54%). Urine (23%). Mometasone: Faeces (74%). Urine (8%).

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.